Posted on August 18th, 2009 in Swine Flu
Crucell NV is currently developing the only adjuvanted flu vaccine against the influenza virus licensed for all age groups but Crucell stock hasn’t match analyst expectations showing a 20% increase since April 2009.
Tags: adjuvants, adjuvants in vaccines, Avi biopharma, avii, BCRX, berna biotech, BioCryst, BioCryst Pharmaceuticals, biotech companies, biotech research, Crucell Berna, crucell influenza, crucell influenza vaccine, Crucell NV, Crucell NV CRXL, Crucell NV Swine Flu, Crucell stock, CRXL, flu pandemic, flu vaccine, H1N1 virus, inflexal, inflexal V, influenza vaccine, influenza virus, introgene, Novavax, NVAX, pandemic crisis, stocks to watch, swine flu pandemic crisis, Swine flu stocks, swine flu stocks to watch, Swine Flu Vaccine, swiss berna, swiss berna biotech, The swine flu, top biotech, top biotech companies, Top Pharmaceutical Companies